Literature DB >> 34887451

Endometrial cancer.

Vicky Makker1,2, Helen MacKay3, Isabelle Ray-Coquard4, Douglas A Levine5,6, Shannon N Westin7, Daisuke Aoki8, Ana Oaknin9.   

Abstract

Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34887451      PMCID: PMC9421940          DOI: 10.1038/s41572-021-00324-8

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   65.038


  227 in total

Review 1.  Molecular and pathologic aspects of endometrial carcinogenesis.

Authors:  Jonathan L Hecht; George L Mutter
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

2.  Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome.

Authors:  Jaclyn C Watkins; Eric J Yang; Michael G Muto; Colleen M Feltmate; Ross S Berkowitz; Neil S Horowitz; Sapna Syngal; Matthew B Yurgelun; Anu Chittenden; Jason L Hornick; Christopher P Crum; Lynette M Sholl; Brooke E Howitt
Journal:  Int J Gynecol Pathol       Date:  2017-03       Impact factor: 2.762

3.  Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Authors:  Brad H Nelson; Jessica N McAlpine; Aline Talhouk; Heather Derocher; Pascal Schmidt; Samuel Leung; Katy Milne; C Blake Gilks; Michael S Anglesio
Journal:  Clin Cancer Res       Date:  2018-12-06       Impact factor: 12.531

4.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

5.  Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.

Authors:  Bengt Sorbe; Britta Nordström; Johanna Mäenpää; Janez Kuhelj; Dimitrij Kuhelj; Sait Okkan; Jean-Francois Delaloye; B Frankendal
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

Review 6.  Type I and II endometrial cancers: have they different risk factors?

Authors:  Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

7.  What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?

Authors:  Nadeem R Abu-Rustum; Dennis S Chi; Mario Leitao; Eniola A Oke; Martee L Hensley; Kaled M Alektiar; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2008-07-26       Impact factor: 5.482

8.  Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.

Authors:  Fei Teng; Wen-Yan Tian; Ying-Mei Wang; Yan-Fang Zhang; Fei Guo; Jing Zhao; Chao Gao; Feng-Xia Xue
Journal:  J Hematol Oncol       Date:  2016-02-06       Impact factor: 17.388

9.  The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.

Authors:  N A J Ryan; M A Glaire; D Blake; M Cabrera-Dandy; D G Evans; E J Crosbie
Journal:  Genet Med       Date:  2019-05-14       Impact factor: 8.822

10.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

View more
  5 in total

1.  Single cell sequencing analysis and transcriptome analysis constructed the liquid-liquid phase separation(LLPS)-related prognostic model for endometrial cancer.

Authors:  Jiayang Wang; Fei Meng; Fei Mao
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

Review 2.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 3.  Current and Emerging Prognostic Biomarkers in Endometrial Cancer.

Authors:  Kelechi Njoku; Chloe E Barr; Emma J Crosbie
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

4.  Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.

Authors:  Heng Ma; Peng-Hui Feng; Shuang-Ni Yu; Zhao-Hui Lu; Qi Yu; Jie Chen
Journal:  BMC Cancer       Date:  2022-05-13       Impact factor: 4.638

5.  Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma.

Authors:  Jing Wang; Weizhen Xing; Yanling Lin; Nuray Uskenbayeva; Hongchao Yan; Yang Xu; Lisha Fang
Journal:  J Clin Lab Anal       Date:  2022-04-14       Impact factor: 3.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.